 MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2020 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that Filippo Petti, Chief Executive Officer, will participate in a fireside chat at the virtual JMP Securities Hematology Summit on Wednesday, December 16, 2020 at 10:00 a.m. ET 4:00 p.m. CET. 